Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep 30:9:5433-8.
doi: 10.2147/DDDT.S87131. eCollection 2015.

A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis

Jin Ah Jung  1 , Tae-Eun Kim  2 , Hyun Lee  3 , Byeong-Ho Jeong  3 , Hye Yun Park  3 , Kyeongman Jeon  3 , O Jung Kwon  3 , Jae-Wook Ko  4 , Rihwa Choi  5 , Hye-In Woo  6 , Won-Jung Koh  3 , Soo-Youn Lee  7
Affiliations

A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis

Jin Ah Jung et al. Drug Des Devel Ther. .

Abstract

Background/aim: Isoniazid (INH) is an essential component of first-line anti-tuberculosis (TB) treatment. However, treatment with INH is complicated by polymorphisms in the expression of the enzyme system primarily responsible for its elimination, N-acetyltransferase 2 (NAT2), and its associated hepatotoxicity. The objective of this study was to develop an individualized INH dosing regimen using a pharmacogenetic-driven model and to apply this regimen in a pilot study.

Methods: A total of 206 patients with TB who received anti-TB treatment were included in this prospective study. The 2-hour post-dose concentrations of INH were obtained, and their NAT2 genotype was determined using polymerase chain reaction and sequencing. A multivariate regression analysis that included the variables of age, sex, body weight, and NAT2 genotype was performed to determine the best model for estimating the INH dose that achieves a concentration of 3.0-6.0 mg/L. This dosing algorithm was then used for newly enrolled 53 patients.

Results: Serum concentrations of INH were significantly lower in the rapid-acetylators than in the slow-acetylators (2.55 mg/L vs 6.78 mg/L, median, P<0.001). A multivariate stepwise linear regression analysis revealed that NAT2 and body weight independently affected INH concentrations: INH concentration (mg/L) = 13.821-0.1× (body weight, kg) -2.273× (number of high activity alleles of NAT2; 0, 1, 2). In 53 newly enrolled patients, the frequency at which they were within the therapeutic range of 3.0-6.0 mg/L was higher in the model-based treatment group compared to the standard treatment group (80.8% vs 59.3%).

Conclusion: The use of individualized pharmacogenetic-guided INH dosage regimens that incorporate NAT2 genotype and body weight may help to ensure achievement of therapeutic concentrations of INH in the TB patients.

Keywords: INH regimen; NAT2 genotype; pharmacogenomics; tuberculosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Individual concentrations of isoniazid relative to body weight (A) and NAT2 genotype (B).
Figure 2
Figure 2
Frequency that patients were within the therapeutic range of 3.0–6.0 mg/L while using standard treatment and model-based treatment. Notes: Frequency within the therapeutic range of 3.0–6.0 mg/L was significantly lower in the group requiring dose changes in the standard treatment group compared to the model-based treatment group (P=0.013). *P<0.05.
See this image and copyright information in PMC

References

    1. World Health Organization Global Health Observatory Tuberculosis. [Accessed February 21, 2015]. Available from: http://www.who.int/gho/tb/en/index.html.
    1. World Health Organization Guidelines for Treatment of Tuberculosis. [Accessed February 23, 2015]. Available from: http://www.who.int/tb/publications/2010/9789241547833/en/
    1. Joint Committee for the Development of Korean Guidelines for TB and Korea Centers for Disease Control and Prevention . Korean Guidelines for Tuberculosis. 2014.
    1. Du H, Chen X, Fang Y, et al. Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis. Mol Biol Rep. 2013;40(5):3591–3596. - PubMed
    1. Wang JY, Liu CH, Hu FC, et al. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect. 2011;62(6):448–455. - PubMed

Publication types

MeSH terms